Center-Authored Papers

Filters: Author is Pagel, J M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Chen X, Newell LF, Xie H, Walter RB, Pagel JM, Sandhu VK, Becker PS, Hendrie PC, Abkowitz JL, Appelbaum FR et al..  2015.  Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.. Leukemia.
G
Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR et al..  2015.  Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 26(11):2323-8. Abstract
Green DJ, Bensinger WI, Holmberg LA, Gooley T, Till BG, Budde LE, Pagel JM, Frayo SL, Roden JE, Hedin L et al..  2016.  Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.. Bone marrow transplantation. Abstract
P
Pagel JM, Matthews DC, Appelbaum FR, Bernstein ID, Press OW.  2002.  The use of radioimmunoconjugates in stem cell transplantation.. Bone marrow transplantation. 29(10):807-16. Abstract
Pham RN, Gooley TA, Keeney GE, Press OW, Pagel JM, Greisman HA, Bensinger WI, Holmberg LA, Petersdorf SH, Maloney DG et al..  2007.  The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma.. Bone marrow transplantation. 40(11):1039-44. Abstract
W
Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR et al..  2015.  Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.. Leukemia. 29(1):137-44. Abstract